Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours

Overview

Journal J Cancer

Specialty Oncology

Date 2014 Aug 27

PMID 25157275

Citations 15

Authors

Fabian Dominik Mairinger

Robert Fred Henry Walter

Dirk Theegarten

Thomas Hager

Claudia Vollbrecht

Daniel Christian Christoph

Karl Worm

Saskia Ting

Robert Werner

Georgios Stamatis

Thomas Mairinger

Hideo Baba

Konstantinos Zarogoulidis

Haidong Huang

Qiang Li

Kosmas Tsakiridis

Paul Zarogoulidis

Kurt Werner Schmid

Jeremias Wohlschlaeger

Affiliations

Soon will be listed here.

Abstract

Background: Proteasomal subunit PSMB4 was suggested to be a survival gene in an animal model of hepatocellular carcinoma and in glioblastoma cell lines. In pulmonary adenocarcinoma, a high expression of these genes was found to be associated with poor differentiation and survival. This study investigates the gene expression levels of 26S proteasome subunits in human pulmonary neuroendocrine tumours including typical (TC) and atypical (AC) carcinoid tumours as well as small cell (SCLC) and large cell (LCNEC) neuroendocrine carcinomas.

Material And Methods: Gene expression levels of proteasomal subunits (PSMA1, PSMA5, PSMB4, PSMB5 and PSMD1) were investigated in 80 neuroendocrine pulmonary tumours (each 20 TC, AC, LCNLC and SCLC) and compared to controls. mRNA levels were determined by using TaqMan assays. Immunohistochemistry on tissue microarrays (TMA) was performed to determine the expression of ki67, cleaved caspase 3 and PSMB4.

Results: All proteasomal subunit gene expressions were significantly upregulated in TC, AC, SCLC and LCNEC compared to controls. PSMB4 mRNA is differently expressed between all neuroendocrine tumour subtypes demonstrating the highest expression and greatest range in LCNEC (p=0.043), and is significantly associated with proliferative activity (p=0.039).

Conclusion: In line with other 26S proteasomal subunits PSMB4 is significantly increased, but differently expressed between pulmonary neuroendocrine tumours and is associated with the proliferative activity. Unlike in pulmonary adenocarcinomas, no association with biological behaviour was observed, suggesting that increased proteasomal subunit gene expression is a common and probably early event in the tumorigenesis of pulmonary neuroendocrine tumours regardless of their differentiation.

Citing Articles

Bioinformatic Analysis Identifying PSMB 1/2/3/4/6/8/9/10 as Prognostic Indicators in Clear Cell Renal Cell Carcinoma.

Guo J, Jing Z, Li X, Liu L Int J Med Sci. 2022; 19(5):796-812.

PMID: 35693739 PMC: 9149646. DOI: 10.7150/ijms.71152.

Bronchial Carcinoids: From Molecular Background to Treatment Approach.

Araujo-Castro M, Pascual-Corrales E, Molina-Cerrillo J, Moreno Mata N, Alonso-Gordoa T Cancers (Basel). 2022; 14(3).

PMID: 35158788 PMC: 8833538. DOI: 10.3390/cancers14030520.

Prognostic and Genomic Analysis of Proteasome 20S Subunit Alpha (PSMA) Family Members in Breast Cancer.

Chiao C, Liu Y, Phan N, An Ton N, Ta H, Anuraga G Diagnostics (Basel). 2021; 11(12).

PMID: 34943457 PMC: 8699889. DOI: 10.3390/diagnostics11122220.

PSMB4 inhibits cardiomyocyte apoptosis via activating NF-κB signaling pathway during myocardial ischemia/reperfusion injury.

Yang C, Yu P, Yang F, He Q, Jiang B, Zheng L J Mol Histol. 2021; 52(4):693-703.

PMID: 33954843 DOI: 10.1007/s10735-021-09977-x.

Association of intronic polymorphisms (rs1549339, rs13402242) and mRNA expression variations in PSMD1 gene in arsenic-exposed workers.

Ahmad S, Arif B, Akram Z, Ahmed M, Khan A, Hussain M Environ Sci Pollut Res Int. 2020; 27(10):11425-11437.

PMID: 31965495 DOI: 10.1007/s11356-019-07422-x.

References

Li B, Dou Q . Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A. 2000; 97(8):3850-5. PMC: 18105. DOI: 10.1073/pnas.070047997. View

Kobrinsky B, Joseph S, Muggia F, Liebes L, Beric A, Malankar A . A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. Cancer Chemother Pharmacol. 2013; 72(5):1073-8. DOI: 10.1007/s00280-013-2295-6. View

Ambati S, Caldas Lopes E, Kosugi K, Mony U, Zehir A, Shah S . Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Mol Oncol. 2014; 8(2):323-36. PMC: 3982393. DOI: 10.1016/j.molonc.2013.12.005. View

van Tijn P, Hol E, van Leeuwen F, Fischer D . The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype. Prog Neurobiol. 2008; 85(2):176-93. DOI: 10.1016/j.pneurobio.2008.03.001. View

Orlowski R, Dees E . The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res. 2003; 5(1):1-7. PMC: 154126. DOI: 10.1186/bcr460. View

Momand J, Zambetti G, Olson D, George D, Levine A . The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69(7):1237-45. DOI: 10.1016/0092-8674(92)90644-r. View

Wang J, Sampath A, Raychaudhuri P, Bagchi S . Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene. 2001; 20(34):4740-9. DOI: 10.1038/sj.onc.1204655. View

Naujokat C, Hoffmann S . Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest. 2002; 82(8):965-80. DOI: 10.1097/01.lab.0000022226.23741.37. View

Elstrom R, Ruan J, Christos P, Martin P, Lebovic D, Osborne J . Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leuk Lymphoma. 2014; 56(2):342-6. PMC: 5176012. DOI: 10.3109/10428194.2014.914195. View

10.

Furman R, Martin P, Ruan J, Cheung Y, Vose J, LaCasce A . Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010; 116(23):5432-9. DOI: 10.1002/cncr.25509. View

11.

Ying H, Xiao Z . Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle. 2006; 5(5):506-8. DOI: 10.4161/cc.5.5.2515. View

12.

Choi Y . Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells. Int J Oncol. 2001; 19(4):687-93. View

13.

Adams J, Palombella V, Elliott P . Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000; 18(2):109-21. DOI: 10.1023/a:1006321828515. View

14.

Cui F, Wang Y, Wang J, Wei K, Hu J, Liu F . The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice. Proteomics. 2005; 6(2):498-504. DOI: 10.1002/pmic.200500218. View

15.

Ciombor K, Feng Y, Benson 3rd A, Su Y, Horton L, Short S . Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 2014; 32(5):1017-27. PMC: 4171216. DOI: 10.1007/s10637-014-0111-8. View

16.

Poklepovic A, Youssefian L, Youseffian L, Winning M, Birdsell C, Crosby N . Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs. 2013; 31(4):937-42. PMC: 3844155. DOI: 10.1007/s10637-012-9913-8. View

17.

Voutsadakis I . The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. J Biomed Sci. 2012; 19:67. PMC: 3418218. DOI: 10.1186/1423-0127-19-67. View

18.

Swarts D, Ramaekers F, Speel E . Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta. 2012; 1826(2):255-71. DOI: 10.1016/j.bbcan.2012.05.001. View

19.

Diehl J, Ponugoti B . Ubiquitin-dependent proteolysis in G1/S phase control and its relationship with tumor susceptibility. Genes Cancer. 2010; 1(7):717-724. PMC: 2991141. DOI: 10.1177/1947601910382902. View

20.

Breitschopf K, Zeiher A, Dimmeler S . Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem. 2000; 275(28):21648-52. DOI: 10.1074/jbc.M001083200. View